Visual disturbance due to retinal edema as a complication of imatinib [1]

Leukemia

Volumn 18, Issue 6, 2004, Pages 1138-1139

  Kusumi, E ^a   Arakawa, A ^a   Kami, M ^b   Kato, D ^a   Yuji, K ^a   Kishi, Y ^b   Murashige, N ^b   Miyakoshi, S ^a   Ueyama, J ^a   Morinaga, S ^a   Taniguchi, S ^a   Muto, Y ^a  

^a TORANOMON HOSPITAL   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; IMATINIB; PREDNISOLONE; PROTEIN TYROSINE KINASE INHIBITOR; VINCRISTINE; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLAST CELL CRISIS; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CASE REPORT; CELL INFILTRATION; CHRONIC MYELOID LEUKEMIA; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; FACE EDEMA; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LETTER; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; RETINA EDEMA; RETINA MACULA EDEMA; VISUAL ACUITY; VISUAL DISORDER; CHEMICALLY INDUCED DISORDER; PAPILLEDEMA;

ADULT; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; LEUKEMIA, MYELOID, CHRONIC; PAPILLEDEMA; PIPERAZINES; PYRIMIDINES; VISION DISORDERS;

EID: 19244365936     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403364     Document Type: Letter

References (8)

1. Schiffer CA, Hehlmann R, Larson R. Perspectives on the treatment of chronic phase and advanced phase CML and Philadelphia chromosome positive ALL(1). Leukemia 2003; 17: 691-699.
2. Savage DC, Antman KH. Imatinib mesylate - a new oral targeted therapy. N Engl J Med 2002; 346: 683-693.
3. Valeyrie L, Bastuji-Garin S, Revuz J, Bachot N, Wechsler J, Berthaud P et al. Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients. J Am Acad Dermatol 2003; 48: 201-206.
4. Lindahl P, Johansson BR, Leveen P, Betsholtz C. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 1997; 277: 242-245.
5. Koleske AJ, Gifford AM, Scott ML, Nee M, Bronson RT, Miczek KA et al. Essential roles for the Abl and Arg tyrosine kinases in neurulation. Neuron 1998; 21: 1259-1272.
6. Fraunfelder FW, Solomon J, Druker BJ, Esmaeli B, Kuyl J. Ocular side-effects associated with imatinib mesylate (Gleevec). J Ocul Pharmacol Ther 2003; 19: 371-375.
7. Robbins SG, Mixon RN, Wilson DJ, Hart CE, Robertson JE, Westra I et al. Platelet-derived growth factor ligands and receptors immunolocalized in proliferative retinal diseases. Invest Ophthalmol Vis Sci 1994; 35: 3649-3663.
8. Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001; 344: 1052-1056.